- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00759525
The Role of Mineralocorticoid Receptors in Vascular Function
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study intends to determine whether activation of mineralocorticoid receptors affects vascular function. Vascular function relies on two components of the blood vessel: the inner lining (endothelium) and the vascular smooth muscle. In specific aim 1, we seek to determine if that inhibition of the enzyme 11-beta hydroxysteroid dehydrogenase (11-beta-HSD) will impair endothelium-dependent vasodilation and/or vascular smooth muscle function.
The syndrome of apparent mineralocorticoid excess (AME) is a rare disorder identified in approximately 50 individuals characterized by low-aldosterone hypertension, associated with low renin and hypokalemia These subjects avidly retain salt and water, have suppression of both plasma renin and aldosterone levels, but clinically appear as though they have a state of mineralocorticoid excess. A detailed series of investigations has elucidated the cause of this syndrome: severe attenuation of the enzyme 11 beta-hydroxysteroid dehydrogenase (11-beta-HSD). 11-beta-HSD converts cortisol, able to activate mineralocorticoid receptors to cortisone, which cannot. This abnormality can be identified by measuring an abnormal ratio of urinary breakdown products of cortisol and cortisone. Subjects with AME have a high ratio indicative of elevated cortisol concentrations.
Although classical AME is a rare syndrome with a specific recessive inheritance, several other mutations have been identified which cause a varying severity of disease. Recent evidence has suggested mild abnormalities in this pathway may be much more common. In fact two studies have demonstrated that subjects with essential hypertension had greater levels of cortisol/cortisone urinary levels than matched controls. Thus, mild abnormalities of this enzyme may be an important contributor to a segment of patients with high blood pressure. Further, this is the pathway by which consumption of excess black licorice causes hypertension. Black licorice contains glycyrrhizic acid that selectively inhibits 11 beta-HSD. Glycyrrhizic acid is used as a dietary sweetener and sold in "health-food" stores and may also play a epidemiological role in hypertension.
Analogous to the renin-angiotensin system, 11-beta-HSD is not only found in the kidneys, but is found in both vascular endothelial (inner lining) and smooth muscle cells. Hypertension, similar to other risk factors for cardiovascular disease impairs vascular function. One of its major effects is decreasing the bioavailability of endothelium-derived nitric oxide. Nitric oxide contributes importantly to vascular homeostasis by modulating vascular tone, inhibiting both platelet aggregation and coagulation, and inhibition translocation of leukocytes into the vascular wall. Further, patients with hypertension have increased endothelin-1 production and receptor activation. Endothelin-1 antagonizes the beneficial activities of nitric oxide. Experimentally, inactivation of 11 beta-HSD in a rat model has been demonstrated to cause hypertension, increase endothelin receptor A activation and decrease bioavailability of endothelium-derived nitric oxide. Inhibition of mineralocorticoid receptors in this model prevents impairment of vascular function. Thus, in animal models, abnormalities in this pathway may not only cause hypertension, but create an environment favorable to the development and progression of atherosclerosis. Further, recent evidence suggests that activation of this pathway contributes importantly to the morbidity and mortality in patients with congestive heart failure. A large, randomized study demonstrated that a small dose of a mineralocorticoid inhibitor, spironolactone, substantially reduced morbidity and mortality in patients with severe heart failure. Experimentally, spironolactone improved vascular function in patients with congestive heart failure.
Therefore, we seek to characterize the vascular effects of this pathway in humans. This submission involves one protocol: 1) to determine if reversible inhibition of 11 beta-HSD decreases the bioavailability of endothelium-derived nitric oxide and impairs vascular smooth muscle function.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy volunteers
Exclusion Criteria:
- Blood pressure above 140/90
- Abnormal physical finding
- Blood test values for total and LDL cholesterol, CBC, sodium, potassium, creatinine, and glucose laboratories greater 1.5 times normal
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
Placebo
|
Placebo daily for fourteen days
|
Active Comparator: 1
Glycyrrhetic Acid
|
130 mg daily for fourteen days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Forearm Blood Flow
Time Frame: Outcome was measured at the end of each study period (i.e. 14 days after Baseline measurements were taken)
|
At the end of each 14-day intervention (Glycyrrhinitic acid or Placebo), vascular endothelial function was assessed by measuring forearm blood flow and comparing to Baseline.
The outcome measure depicted below reflects the change in forearm blood flow from Baseline after completing the glycyrrhinitic acid regimen as well as the change in forearm blood flow from Baseline after taking the matching placebo.
|
Outcome was measured at the end of each study period (i.e. 14 days after Baseline measurements were taken)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joshua A Beckman, MD, Brigham and Women's Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2001-P-001404
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Apparent Mineralocorticoid Excess (AME)
-
Icahn School of Medicine at Mount SinaiEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedApparent Mineralocorticoid Excess SyndromeUnited States, Brazil, France
-
The Royal Wolverhampton Hospitals NHS TrustCompletedApparent Mineralocorticoid ExcessUnited Kingdom
-
Brigham and Women's HospitalRecruiting
-
Institut National de la Santé Et de la Recherche...UnknownChoroidal Neovascularization | Mineralocorticoid Excess
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingHypertension | Primary Aldosteronism | Hyperaldosteronism | Resistant Hypertension | Mineralocorticoid Excess | Secondary HypertensionUnited States
-
Changi General HospitalSingapore General HospitalRecruitingPrimary Aldosteronism | Hypokalemia | Chronic Renal Disease | Cardiovascular Morbidity | Mineralocorticoid Excess | Adrenalectomy; Status | Primary Aldosteronism Due to Aldosterone Producing Adenoma | Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral) | Mineralocorticoid Antagonists [Aldosterone...Singapore
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsEnrolling by invitationPrimary Hyperoxaluria Type 3 | Diabetes Mellitus | Hemophilia A | Hemophilia B | Hereditary Fructose Intolerance | Cystic Fibrosis | Factor VII Deficiency | Phenylketonurias | Sickle Cell Disease | Dravet Syndrome | Duchenne Muscular Dystrophy | Prader-Willi Syndrome | Fragile X Syndrome | Chronic Granulomatous Disease and other conditionsUnited States
Clinical Trials on Glycyrrhetic Acid
-
Russell SwerdlowCompleted
-
Vanderbilt UniversityNational Cancer Institute (NCI)CompletedColorectal Adenomatous PolypsUnited States
-
Universitaire Ziekenhuizen KU LeuvenCompletedHealthy VolunteersBelgium
-
Dr. Falk Pharma GmbHRecruiting
-
Société des Produits Nestlé (SPN)Completed
-
Leeds Beckett UniversityNot yet recruitingRheumatoid Arthritis | Muscle Atrophy
-
Syracuse UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedEssential Voice Tremor | Voice Tremor | Vocal Tremor | Essential Tremor of VoiceUnited States
-
University Hospital, Basel, SwitzerlandCompleted
-
Hadassah Medical OrganizationCompletedThrombocytopenia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRefractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic SyndromeUnited States